Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.

Philip A Philip Ibrahim Hanna AzarJoanne XiuMichael J HallAndrew Eugene HendifarEmil LouJimmy J HwangJun GongRebecca A Feldman Michelle EllisPhil StaffordDavid SpetzlerMoh'd M KhushmanDavendra SohalA Craig LockhartBenjamin A WeinbergWafik S El-DeiryJohn L Marshall Anthony Frank Shields Wolfgang Michael Korn

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

KRAS WT PDAC represents 10.7% of PDAC and is enriched with targetable alterations, including immuno-oncologic markers. Identification of KRAS WT patients in clinical practice may expand therapeutic options in a clinically meaningful manner.

Keyphrases

wild type
end stage renal disease
clinical practice
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prostate cancer
rectal cancer
minimally invasive